West Moreton Health’s Clinical Trials Unit continues to build momentum with the launch of the major adverse liver outcomes (MALO) clinical trial under the leadership of Dr Thomas Dover.
The study is now fully operational at West Moreton Health, showcasing the unit’s ability to rapidly activate and deliver complex trials.
The MALO study is a cutting-edge trial using an innovative 'umbrella' design to test multiple treatments for high-risk metabolic dysfunction-associated steatotic liver disease.
The trial helps place West Moreton Health at the forefront of advancing therapies in endocrinology and metabolic disease.
Recruitment for the trial is underway, reflecting the expertise, coordination and dedication of the Clinical Trials Unit in providing patients with access to emerging treatments.
West Moreton Health's Clinical Trials and Cardiology teams have also expanded the MOVE-Lp(a) clinical trial from Ipswich Hospital to Gatton Hospital.
This expansion will be delivered through the Cardiac Outreach Clinic, led by Dr James Robinson.
MOVE-Lp(a) is investigating the effect of Muvalaplin in reducing major cardiovascular events in adults with elevated lipoprotein(a), a significant inherited risk factor for cardiovascular disease.
The trial provides local patients with the opportunity to be screened for cardiovascular risk while contributing to innovative research across the health service.
The trial is led at Ipswich Hospital by Principal Investigator Dr Johanne Neill, with Dr Robinson serving as Associate Investigator at the Gatton site.
Study coordination is led by Clinical Trials Coordinator Fiona Davis, supported by Gatton Hospital Community Health Nurse Sandra Stronach.
More information on the trials is available in the latest edition of West Moreton Health's quarterly research newsletter, Research Online News.